vTv Therapeutics Inc. (VTVT)Healthcare | Biotechnology | High Point, United States | NasdaqCM
31.58 USD
-1.91
(-5.703%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 31.65 +0.07 (0.222%) ⇧ (July 13, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:21 a.m. EDT
The immediate outlook remains neutral despite a recent bounce, as the asset lacks a clear directional edge for a near-term trade. While the price has rallied from its lows, the underlying business fundamentals are severely compromised by a decade-long structural decline, with the stock down nearly 93% over the last nine years. This prolonged erosion suggests the market views the current operations as insufficient to reverse the trend, rendering any 'value' narrative a trap rather than a bargain. Compounding the distress is the company's inability to generate sustainable earnings, with forward estimates showing significant losses and a balance sheet that relies entirely on cash reserves rather than organic profitability. Furthermore, the complete absence of a dividend program eliminates any income floor for investors. Although analysts have raised price targets implying substantial upside, these projections appear disconnected from the harsh reality of the company's deteriorating trajectory and lack of proven revenue growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.084324 |
| AutoETS | 0.094618 |
| AutoARIMA | 0.094619 |
| MSTL | 0.100346 |
| MSTL_37 | 0.103415 |
| MSTL_97 | 0.114726 |
| MSTL_37_97 | 0.125204 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.508 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.729 |
| Market Cap | 124,382,696 |
| Forward P/E | -8.11 |
| Beta | 0.25 |
| Profit Margins | 6.11% |
| Website | https://vtvtherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.004189 |
| Address1 | 3,980 Premier Drive |
| Address2 | Suite 310 |
| All Time High | 560.0 |
| All Time Low | 7.38 |
| Ask | 32.3 |
| Ask Size | 10 |
| Average Daily Volume10 Day | 65,320 |
| Average Daily Volume3 Month | 51,872 |
| Average Volume | 51,872 |
| Average Volume10Days | 65,320 |
| Beta | 0.252 |
| Bid | 31.95 |
| Bid Size | 3 |
| Book Value | 7.249 |
| City | High Point |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.58 |
| Current Ratio | 14.36 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 33.0 |
| Day Low | 31.33 |
| Display Name | vTv Therapeutics |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -3,034,000 |
| Ebitda Margins | -0.08236 |
| Enterprise To Ebitda | -96.836 |
| Enterprise To Revenue | 7.975 |
| Enterprise Value | 293,799,008 |
| Eps Current Year | -2.09833 |
| Eps Forward | -3.89167 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 336 841 0310 |
| Fifty Day Average | 33.7007 |
| Fifty Day Average Change | -2.120699 |
| Fifty Day Average Change Percent | -0.06292745 |
| Fifty Two Week Change Percent | 100.4189 |
| Fifty Two Week High | 44.0 |
| Fifty Two Week High Change | -12.42 |
| Fifty Two Week High Change Percent | -0.28227273 |
| Fifty Two Week Low | 14.0 |
| Fifty Two Week Low Change | 17.58 |
| Fifty Two Week Low Change Percent | 1.2557143 |
| Fifty Two Week Range | 14.0 - 44.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,438,263,000,000 |
| Float Shares | 2,143,703 |
| Forward Eps | -3.89167 |
| Forward P E | -8.114768 |
| Free Cashflow | 5,278,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 26 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.34827 |
| Gross Profits | 12,830,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.38979998 |
| Held Percent Institutions | 0.38429 |
| Implied Shares Outstanding | 3,938,654 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,700,524,800 |
| Last Split Factor | 1:40 |
| Long Business Summary | vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina. |
| Long Name | vTv Therapeutics Inc. |
| Market | us_market |
| Market Cap | 124,382,696 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_304063261 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 2,252,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 131,905,522 |
| Number Of Analyst Opinions | 6 |
| Open | 33.0 |
| Operating Cashflow | -10,414,000 |
| Operating Margins | 0.63148 |
| Payout Ratio | 0.0 |
| Phone | 336 841 0300 |
| Post Market Change | 0.069999695 |
| Post Market Change Percent | 0.22165832 |
| Post Market Price | 31.65 |
| Post Market Time | 1,783,986,802 |
| Previous Close | 33.49 |
| Price Eps Current Year | -15.050063 |
| Price Hint | 2 |
| Price To Book | 4.356463 |
| Price To Sales Trailing12 Months | 3.3763864 |
| Profit Margins | 0.06113 |
| Quick Ratio | 14.255 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.91 |
| Regular Market Change Percent | -5.7032 |
| Regular Market Day High | 33.0 |
| Regular Market Day Low | 31.33 |
| Regular Market Day Range | 31.33 - 33.0 |
| Regular Market Open | 33.0 |
| Regular Market Previous Close | 33.49 |
| Regular Market Price | 31.58 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 41,649 |
| Return On Assets | -0.029059999 |
| Return On Equity | -0.01475 |
| Revenue Per Share | 3.729 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,938,654 |
| Shares Percent Shares Out | 0.0416 |
| Shares Short | 163,681 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 157,260 |
| Short Name | vTv Therapeutics Inc. |
| Short Percent Of Float | 0.0687 |
| Short Ratio | 3.19 |
| Source Interval | 15 |
| State | NC |
| Symbol | VTVT |
| Target High Price | 67.0 |
| Target Low Price | 44.0 |
| Target Mean Price | 53.0 |
| Target Median Price | 52.0 |
| Total Cash | 98,086,000 |
| Total Cash Per Share | 7.904 |
| Total Debt | 0 |
| Total Revenue | 36,839,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.576237 |
| Two Hundred Day Average Change | -0.9962368 |
| Two Hundred Day Average Change Percent | -0.030581703 |
| Type Disp | Equity |
| Volume | 41,649 |
| Website | https://vtvtherapeutics.com |
| Zip | 27,265 |